<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endofocus</journal-id><journal-title-group><journal-title xml:lang="ru">FOCUS Эндокринология</journal-title><trans-title-group xml:lang="en"><trans-title>FOCUS. Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-0177</issn><issn pub-type="epub">2713-0185</issn><publisher><publisher-name>ООО "Издательство "Перо"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.62751/2713-0177-2024-5-4-18</article-id><article-id custom-type="elpub" pub-id-type="custom">endofocus-127</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LITERATURE REVIEW</subject></subj-group></article-categories><title-group><article-title>Медикаментозная терапия ожирения: современные подходы и перспективы</article-title><trans-title-group xml:lang="en"><trans-title>Medical treatment of obesity: Modern approaches and prospects</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8684-6095</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Титова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Titova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Титова Виктория Викторовна – ассистент кафедры эндокринологии института клинической медицины </p><p>Москва</p></bio><bio xml:lang="en"><p>Victoria V. Titova –  assistant at the Department of Endocrinology Medical Faculty</p><p>Moscow</p></bio><email xlink:type="simple">meteora-vica@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5512-6899</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ушанова</surname><given-names>Ф. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Ushanova</surname><given-names>F. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ушанова Фатима Омариевна – к.м.н., доцент кафедры эндокринологии ИКМ </p><p>Москва</p></bio><bio xml:lang="en"><p>Fatima O. Ushanova – Can. Sci. (Med.), Associate Professor of the Department of Endocrinology of the Faculty of Medicine</p><p>Moscow</p></bio><email xlink:type="simple">fati_2526@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6385-540X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демидова</surname><given-names>Т. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Demidova</surname><given-names>T. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Демидова Татьяна Юльевна – д. м. н., профессор, заведующая кафедрой эндокринологии института клинической медицины</p><p>Москва</p></bio><bio xml:lang="en"><p>Tatiana Yu. Demidova – D. Sci. (Med.), Prof.</p><p>Moscow</p></bio><email xlink:type="simple">t.y.demidova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»</institution></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>25</day><month>12</month><year>2024</year></pub-date><volume>5</volume><issue>4</issue><fpage>40</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Титова В.В., Ушанова Ф.О., Демидова Т.Ю., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Титова В.В., Ушанова Ф.О., Демидова Т.Ю.</copyright-holder><copyright-holder xml:lang="en">Titova V.V., Ushanova F.O., Demidova T.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://endofocus.elpub.ru/jour/article/view/127">https://endofocus.elpub.ru/jour/article/view/127</self-uri><abstract><p>Ожирение – хроническое прогрессирующее заболевание, представляющее большую проблему для современного здравоохранения ввиду высокой и быстрорастущей распространенности и развития тяжелых осложнений, таких как сердечно-сосудистые заболевания, сахарный диабет 2 типа, злокачественные новообразования и др. Эффективное лечение ожирения требует комплексного подхода, где медикаментозная терапия и в некоторых случаях бариатрическое вмешательство дополняют меры по изменению образа жизни – коррекцию питания и применение регулярных физических нагрузок. Для успешного лечения ожирения необходим индивидуальный подход к пациенту с учетом исходной массы тела, наличия факторов риска или уже развившихся сопутствующих заболеваний, а также динамики снижения веса на фоне терапии. Медикаментозная терапия служит важной частью лечения ожирения, так как позволяет достичь более значимого снижения массы тела и, что немаловажно, удержать сниженный вес. Препараты класса агонистов рецепторов глюкагоноподобного пептида-1, широко применяющиеся сегодня в лечении ожирения, не только влияют непосредственно на массу тела, но и снижают риски тяжелых сердечно-сосудистых заболеваний и метаболических нарушений, приводя таким образом к улучшению качества жизни и увеличению ее продолжительности. В статье представлены основные подходы к лечению пациентов с ожирением с описанием современных возможностей фармакологического лечения.</p></abstract><trans-abstract xml:lang="en"><p>Obesity is a chronic progressive disease that poses a major problem for modern healthcare due to the high and rapidly growing prevalence and development of severe complications such as cardiovascular diseases, type 2 diabetes mellitus, malignant neoplasms, etc. Effective treatment of obesity requires an integrated approach, where drug therapy and, in some cases, bariatric intervention complement lifestyle measures – nutrition correction and the use of regular physical activity. Successful treatment of obesity requires an individual approach to the patient, taking into account the initial body weight, the presence of risk factors or developed concomitant diseases, as well as the dynamics of weight loss during therapy. Drug therapy is an important part of the treatment of obese patients, because it allows you to achieve a more significant result of weight loss, and, importantly, to maintain a reduced weight. Drugs of the GLP-1 agonists, widely used today in the treatment of obesity, not only directly affect body weight, but also reduce the risks of severe cardiovascular diseases and metabolic disorders, thus leading to an improvement in the quality of life and an increase in its duration. The article presents the main approaches to the treatment of obese patients with a description of the modern possibilities of pharmacological treatment of obesity.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>снижение массы тела</kwd><kwd>агонисты рецепторов глюкагоноподобного пептида-1</kwd><kwd>сердечно-сосудистые исходы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>weight loss</kwd><kwd>glucagon-like peptide-1 receptor agonists</kwd><kwd>cardiovascular outcomes</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022; 1: 100004. doi:10.1016/j.obpill.2021.100004.</mixed-citation><mixed-citation xml:lang="en">Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022; 1: 100004. doi:10.1016/j.obpill.2021.100004.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Здравоохранение в России. 2023: Стат.сб./Росстат. М.: З-46. 2023; 179 с. Доступ: https://rosstat.gov.ru/folder/210/document/13218 (дата обращения – 01.11.2024).</mixed-citation><mixed-citation xml:lang="en">Здравоохранение в России. 2023: Стат.сб./Росстат. М.: З-46. 2023; 179 с. Доступ: https://rosstat.gov.ru/folder/210/document/13218 (дата обращения – 01.11.2024).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017; 6(2): 187–94. doi: 10.1007/s13679-017-0262-y.</mixed-citation><mixed-citation xml:lang="en">Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017; 6(2): 187–94. doi: 10.1007/s13679-017-0262-y.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. с соавт. Ожирение. Клинические рекомендации. Consilium Medicum. 2021; 23(4): 311–325. doi: 10.26442/20751753.2021.4.200832.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. с соавт. Ожирение. Клинические рекомендации. Consilium Medicum. 2021; 23(4): 311–325. doi: 10.26442/20751753.2021.4.200832.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sherrington A, Newham JJ, Bell R et al. Systematic review and meta-analysis of internet-delivered interventions providing personalized feedback for weight loss in overweight and obese adults. Obes Rev. 2016; 17(6): 541–51. doi: 10.1111/obr.12396.</mixed-citation><mixed-citation xml:lang="en">Sherrington A, Newham JJ, Bell R et al. Systematic review and meta-analysis of internet-delivered interventions providing personalized feedback for weight loss in overweight and obese adults. Obes Rev. 2016; 17(6): 541–51. doi: 10.1111/obr.12396.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wadden TA, Neiberg RH, Wing RR et al.; Look AHEAD Research Group. Four-year weight losses in the Look AHEAD study: Factors associated with long-term success. Obesity (Silver Spring). 2011; 19(10): 1987–98. doi:10.1038/oby.2011.230.</mixed-citation><mixed-citation xml:lang="en">Wadden TA, Neiberg RH, Wing RR et al.; Look AHEAD Research Group. Four-year weight losses in the Look AHEAD study: Factors associated with long-term success. Obesity (Silver Spring). 2011; 19(10): 1987–98. doi:10.1038/oby.2011.230.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Karam G, Agarwal A, Sadeghirad B et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: Systematic review and network meta-analysis. BMJ. 2023; 380: e072003. doi: 10.1136/bmj-2022-072003.</mixed-citation><mixed-citation xml:lang="en">Karam G, Agarwal A, Sadeghirad B et al. Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: Systematic review and network meta-analysis. BMJ. 2023; 380: e072003. doi: 10.1136/bmj-2022-072003.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dinu M, Pagliai G, Angelino D et al. Effects of popular diets on anthropometric and cardiometabolic parameters: An umbrella review of meta-analyses of randomized controlled trials. Adv Nutr. 2020; 11(4): 815–33. doi: 10.1093/advances/nmaa006.</mixed-citation><mixed-citation xml:lang="en">Dinu M, Pagliai G, Angelino D et al. Effects of popular diets on anthropometric and cardiometabolic parameters: An umbrella review of meta-analyses of randomized controlled trials. Adv Nutr. 2020; 11(4): 815–33. doi: 10.1093/advances/nmaa006.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Piercy KL, Troiano RP, Ballard RM et al. The physical activity guidelines for Americans. JAMA. 2018; 320(19): 2020–28. doi: 10.1001/jama.2018.14854.</mixed-citation><mixed-citation xml:lang="en">Piercy KL, Troiano RP, Ballard RM et al. The physical activity guidelines for Americans. JAMA. 2018; 320(19): 2020–28. doi: 10.1001/jama.2018.14854.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1): 155–61. doi: 10.2337/diacare.27.1.155.</mixed-citation><mixed-citation xml:lang="en">Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27(1): 155–61. doi: 10.2337/diacare.27.1.155.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Демидова Т.Ю., Измайлова М.Я., Ушакова С.Е. с соавт. Оценка эффективности снижения веса и безопасности применения сибутраминсодержащих лекарственных препаратов у пациентов с алиментарным ожирением. Фармация и фармакология. 2022; 10(3): 289–304. doi: 10.19163/2307-9266-2022-10-3-289-304.</mixed-citation><mixed-citation xml:lang="en">Демидова Т.Ю., Измайлова М.Я., Ушакова С.Е. с соавт. Оценка эффективности снижения веса и безопасности применения сибутраминсодержащих лекарственных препаратов у пациентов с алиментарным ожирением. Фармация и фармакология. 2022; 10(3): 289–304. doi: 10.19163/2307-9266-2022-10-3-289-304.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003; 27(12): 1437–46. doi: 10.1038/sj.ijo.0802475.</mixed-citation><mixed-citation xml:lang="en">Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003; 27(12): 1437–46. doi: 10.1038/sj.ijo.0802475.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">James WPT, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet. 2000; 356(9248): 2119–25. doi: 10.1016/s0140-6736(00)03491-7.</mixed-citation><mixed-citation xml:lang="en">James WPT, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet. 2000; 356(9248): 2119–25. doi: 10.1016/s0140-6736(00)03491-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкции по медицинскому применению лекарственных препаратов с МНН лираглутид. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/GRLS.aspx-?RegNumber=&amp;MnnR=лираглутид&amp;lf=&amp;TradeNmR=&amp;OwnerName=&amp;MnfOrg=&amp;MnfOrgCountry=&amp;isfs=0&amp;regtype=12c6&amp;pageSize=10&amp;token=4cc2b604-5e85-4461-908d-c32ad2a79ed1&amp;order=Registered&amp;orderType=-desc&amp;pageNum=1 (дата обращения – 01.11.2024).</mixed-citation><mixed-citation xml:lang="en">Инструкции по медицинскому применению лекарственных препаратов с МНН лираглутид. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/GRLS.aspx-?RegNumber=&amp;MnnR=лираглутид&amp;lf=&amp;TradeNmR=&amp;OwnerName=&amp;MnfOrg=&amp;MnfOrgCountry=&amp;isfs=0&amp;regtype=12c6&amp;pageSize=10&amp;token=4cc2b604-5e85-4461-908d-c32ad2a79ed1&amp;order=Registered&amp;orderType=-desc&amp;pageNum=1 (дата обращения – 01.11.2024).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marso SP, Bain SC, Consoli A et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–44. doi: 10.1056/NEJMoa1607141.</mixed-citation><mixed-citation xml:lang="en">Marso SP, Bain SC, Consoli A et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–44. doi: 10.1056/NEJMoa1607141.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wadden TA, Tronieri JS, Sugimoto D et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020; 28(3): 529–36. doi: 10.1002/oby.22726.</mixed-citation><mixed-citation xml:lang="en">Wadden TA, Tronieri JS, Sugimoto D et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020; 28(3): 529–36. doi: 10.1002/oby.22726.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pi-Sunyer X, Astrup A, Fujioka K et al.; SCALE Obesity and Prediabetes NN8022- 1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373(1): 11–22. doi: 10.1056/NEJMoa1411892.</mixed-citation><mixed-citation xml:lang="en">Pi-Sunyer X, Astrup A, Fujioka K et al.; SCALE Obesity and Prediabetes NN8022- 1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373(1): 11–22. doi: 10.1056/NEJMoa1411892.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Аметов А.С., Шохин И.Е., Рогожина Е.А. с соавт. Российская разработка для лекарственной независимости в эндокринологии: сравнительный анализ биоэквивалентности, безопасности и переносимости первого отечественного лираглутида. Фармация и фармакология. 2023; 11(3): 255–276. doi: 10.19163/2307-9266-2023-11-3-255-276.</mixed-citation><mixed-citation xml:lang="en">Аметов А.С., Шохин И.Е., Рогожина Е.А. с соавт. Российская разработка для лекарственной независимости в эндокринологии: сравнительный анализ биоэквивалентности, безопасности и переносимости первого отечественного лираглутида. Фармация и фармакология. 2023; 11(3): 255–276. doi: 10.19163/2307-9266-2023-11-3-255-276.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41(2): 258–66. doi: 10.2337/dc17-0417.</mixed-citation><mixed-citation xml:lang="en">Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41(2): 258–66. doi: 10.2337/dc17-0417.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Thethi TK, Pratley R, Efficacy MJJ. Safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020; 22(8): 1263–77. doi: 10.1111/dom.14054.</mixed-citation><mixed-citation xml:lang="en">Thethi TK, Pratley R, Efficacy MJJ. Safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020; 22(8): 1263–77. doi: 10.1111/dom.14054.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384(11): 989–1002. doi: 10.1056/NEJMoa2032183.</mixed-citation><mixed-citation xml:lang="en">Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384(11): 989–1002. doi: 10.1056/NEJMoa2032183.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Davies M, Faerch L, Jeppesen OK et al.; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971–84. doi: 10.1016/S0140-6736(21)00213-0.</mixed-citation><mixed-citation xml:lang="en">Davies M, Faerch L, Jeppesen OK et al.; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971–84. doi: 10.1016/S0140-6736(21)00213-0.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wadden TA, Bailey TS, Billings LK et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021; 325(14): 1403–13. doi: 10.1001/jama.2021.1831.</mixed-citation><mixed-citation xml:lang="en">Wadden TA, Bailey TS, Billings LK et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021; 325(14): 1403–13. doi: 10.1001/jama.2021.1831.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Rubino D, Abrahamsson N, Davies M et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021; 325(14): 1414–25. doi: 10.1001/jama.2021.3224.</mixed-citation><mixed-citation xml:lang="en">Rubino D, Abrahamsson N, Davies M et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021; 325(14): 1414–25. doi: 10.1001/jama.2021.3224.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 2022; 28(10): 2083–91. doi: 10.1038/s41591-022-02026-4.</mixed-citation><mixed-citation xml:lang="en">Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 2022; 28(10): 2083–91. doi: 10.1038/s41591-022-02026-4.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rubino DM, Greenway FL, Khalid U et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022; 327(2): 138–50. doi: 10.1001/jama.2021.23619.</mixed-citation><mixed-citation xml:lang="en">Rubino DM, Greenway FL, Khalid U et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022; 327(2): 138–50. doi: 10.1001/jama.2021.23619.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Deanfield J, Verma S, Scirica BM et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404(10454): 773–86. doi: 10.1016/S0140-6736(24)01498-3.</mixed-citation><mixed-citation xml:lang="en">Deanfield J, Verma S, Scirica BM et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404(10454): 773–86. doi: 10.1016/S0140-6736(24)01498-3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kosiborod MN, Abildstrøm SZ, Borlaug BA et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12): 1069–84. doi: 10.1056/NEJMoa2306963.</mixed-citation><mixed-citation xml:lang="en">Kosiborod MN, Abildstrøm SZ, Borlaug BA et al.; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12): 1069–84. doi: 10.1056/NEJMoa2306963.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang R, Hou QC, Li BH et al. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: A subgroup meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023; 14: 1132004. doi: 10.3389/fendo.2023.1132004.</mixed-citation><mixed-citation xml:lang="en">Zhang R, Hou QC, Li BH et al. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: A subgroup meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023; 14: 1132004. doi: 10.3389/fendo.2023.1132004.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/ (дата обращения – 01.11.2024).</mixed-citation><mixed-citation xml:lang="en">Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/ (дата обращения – 01.11.2024).</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Jastreboff AM, Aronne LJ, Ahmad NN et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205–16. doi: 10.1056/NEJMoa2206038.</mixed-citation><mixed-citation xml:lang="en">Jastreboff AM, Aronne LJ, Ahmad NN et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205–16. doi: 10.1056/NEJMoa2206038.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lean MEJ, Leslie WS, Barnes AC et al. Durability of a primary careled weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019; 7(5): 344–55. doi: 10.1016/S2213-8587(19)30068-3.</mixed-citation><mixed-citation xml:lang="en">Lean MEJ, Leslie WS, Barnes AC et al. Durability of a primary careled weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019; 7(5): 344–55. doi: 10.1016/S2213-8587(19)30068-3.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
